Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ALMS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Sanam Pangali Chief Legal Officer | ALMS Alumis Inc. | Sale | 332 | $6.52 | $2,165 Sale | Form 4 ↗ |
| Nov 2, 2026 | Mark Christopher Bradley Chief Development Officer | ALMS Alumis Inc. | Sale | 623 | $6.52 | $4,062 Sale | Form 4 ↗ |
| Nov 2, 2026 | Jorn Drappa Chief Medical Officer | ALMS Alumis Inc. | Sale | 593 | $6.52 | $3,866 Sale | Form 4 ↗ |
| Nov 2, 2026 | David M. Goldstein Chief Scientific Officer | ALMS Alumis Inc. | Sale | 629 | $6.52 | $4,101 Sale | Form 4 ↗ |
| Nov 2, 2026 | John R. Schroer Chief Financial Officer | ALMS Alumis Inc. | Sale | 794 | $6.52 | $5,177 Sale | Form 4 ↗ |
| Nov 2, 2026 | Roy C. Hardiman Chief Business & Strategy Ofcr | ALMS Alumis Inc. | Sale | 652 | $6.52 | $4,251 Sale | Form 4 ↗ |
| Sep 8, 2026 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 273,290 | $10.63 | $2.9M Buy | Form 4 ↗ |
| Sep 8, 2026 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 273,291 | $10.63 | $2.9M Buy | Form 4 ↗ |
| Sep 8, 2026 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Sale | 48,065 | $10.55 | $507.1K Sale | Form 4 ↗ |
| Sep 8, 2026 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Sale | 48,066 | $10.55 | $507.1K Sale | Form 4 ↗ |
| Sep 4, 2026 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 220,070 | $11.17 | $2.5M Buy | Form 4 ↗ |
| Sep 4, 2026 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 220,070 | $11.17 | $2.5M Buy | Form 4 ↗ |
| Aug 3, 2026 | Sanam Pangali Chief Legal Officer | ALMS Alumis Inc. | Sale | 1,364 | $26.37 | $36.0K Sale | Form 4 ↗ |
| Aug 3, 2026 | Mark Christopher Bradley Chief Development Officer | ALMS Alumis Inc. | Sale | 2,572 | $26.37 | $67.8K Sale | Form 4 ↗ |
| Aug 3, 2026 | Jorn Drappa Chief Medical Officer | ALMS Alumis Inc. | Sale | 2,447 | $26.37 | $64.5K Sale | Form 4 ↗ |
| Aug 3, 2026 | David M. Goldstein Chief Scientific Officer | ALMS Alumis Inc. | Sale | 2,596 | $26.37 | $68.5K Sale | Form 4 ↗ |
| Aug 3, 2026 | John R. Schroer Chief Financial Officer | ALMS Alumis Inc. | Sale | 3,282 | $26.37 | $86.5K Sale | Form 4 ↗ |
| Aug 3, 2026 | Roy C. Hardiman Chief Business & Strategy Ofcr | ALMS Alumis Inc. | Sale | 2,692 | $26.37 | $71.0K Sale | Form 4 ↗ |
| Jul 6, 2026 | Sanam Pangali Chief Legal Officer | ALMS Alumis Inc. | Sale | 5,000 | $28.00 | $140.0K Sale | Form 4 ↗ |
| Jan 9, 2026 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 588,235 | $17.00 | $10.0M Buy | Form 4 ↗ |
| Jan 8, 2026 | Foresite Labs, LLC 10% owner | ALMS Alumis Inc. | Buy | 294,117 | $17.00 | $5.0M Buy | Form 4 ↗ |
| Jan 8, 2026 | Foresite Labs, LLC 10% owner | ALMS Alumis Inc. | Buy | 117,647 | $17.00 | $2.0M Buy | Form 4 ↗ |
| Jan 8, 2026 | Foresite Labs Fund I, L.P. 10% owner | ALMS Alumis Inc. | Buy | 294,117 | $17.00 | $5.0M Buy | Form 4 ↗ |
| Jan 8, 2026 | Foresite Labs Fund I, L.P. 10% owner | ALMS Alumis Inc. | Buy | 117,647 | $17.00 | $2.0M Buy | Form 4 ↗ |
| Jan 8, 2026 | James B. Tananbaum Director, 10% owner | ALMS Alumis Inc. | Buy | 294,117 | $17.00 | $5.0M Buy | Form 4 ↗ |
| Jan 8, 2026 | James B. Tananbaum Director, 10% owner | ALMS Alumis Inc. | Buy | 117,647 | $17.00 | $2.0M Buy | Form 4 ↗ |
| Dec 5, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 51,380 | $10.73 | $551.3K Buy | Form 4 ↗ |
| Dec 5, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 70,028 | $10.01 | $701.0K Buy | Form 4 ↗ |
| Dec 5, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 64,969 | $8.95 | $581.5K Buy | Form 4 ↗ |
| Dec 4, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 66,027 | $8.18 | $540.1K Buy | Form 4 ↗ |
| Dec 3, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 100,000 | $7.75 | $775.0K Buy | Form 4 ↗ |
| Dec 2, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 96,000 | $7.55 | $724.8K Buy | Form 4 ↗ |
| Dec 1, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 86,350 | $7.46 | $644.2K Buy | Form 4 ↗ |
| Nov 28, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 38,702 | $7.64 | $295.7K Buy | Form 4 ↗ |
| Nov 26, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 48,537 | $7.64 | $370.8K Buy | Form 4 ↗ |
| Nov 21, 2025 | Foresite Labs Fund I, L.P. 10% owner | ALMS Alumis Inc. | Buy | 72,212 | $7.38 | $532.9K Buy | Form 4 ↗ |
| Nov 21, 2025 | James B. Tananbaum Director, 10% owner | ALMS Alumis Inc. | Buy | 72,212 | $7.38 | $532.9K Buy | Form 4 ↗ |
| Nov 21, 2025 | Foresite Labs Affiliates 2021, LLC 10% owner | ALMS Alumis Inc. | Buy | 72,212 | $7.38 | $532.9K Buy | Form 4 ↗ |
| Nov 20, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 125,743 | $7.20 | $905.3K Buy | Form 4 ↗ |
| Nov 19, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 137,772 | $6.56 | $903.8K Buy | Form 4 ↗ |
| Nov 19, 2025 | Foresite Labs Affiliates 2021, LLC 10% owner | ALMS Alumis Inc. | Buy | 190,500 | $6.56 | $1.2M Buy | Form 4 ↗ |
| Nov 19, 2025 | Foresite Capital Management VI LLC 10% owner | ALMS Alumis Inc. | Buy | 190,500 | $6.56 | $1.2M Buy | Form 4 ↗ |
| Nov 19, 2025 | James B. Tananbaum Director, 10% owner | ALMS Alumis Inc. | Buy | 190,500 | $6.56 | $1.2M Buy | Form 4 ↗ |
| Nov 18, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 102,652 | $6.05 | $621.0K Buy | Form 4 ↗ |
| Nov 18, 2025 | Foresite Labs Affiliates 2021, LLC 10% owner | ALMS Alumis Inc. | Buy | 117,374 | $6.19 | $726.5K Buy | Form 4 ↗ |
| Nov 18, 2025 | Foresite Capital Management VI LLC 10% owner | ALMS Alumis Inc. | Buy | 117,374 | $6.19 | $726.5K Buy | Form 4 ↗ |
| Nov 18, 2025 | James B. Tananbaum Director, 10% owner | ALMS Alumis Inc. | Buy | 117,374 | $6.19 | $726.5K Buy | Form 4 ↗ |
| Nov 17, 2025 | Srinivas Akkaraju Director | ALMS Alumis Inc. | Buy | 914 | $5.51 | $5,036 Buy | Form 4 ↗ |
| Nov 17, 2025 | Foresite Labs Affiliates 2021, LLC 10% owner | ALMS Alumis Inc. | Buy | 150,000 | $5.59 | $838.5K Buy | Form 4 ↗ |
| Nov 17, 2025 | Foresite Labs Affiliates 2021, LLC 10% owner | ALMS Alumis Inc. | Buy | 50,000 | $5.60 | $280.0K Buy | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances